GRNA Stock Overview
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
My Notes
NewNotes are coming soon
GreenLight Biosciences Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$15.80 |
| 52 Week Low | US$1.00 |
| Beta | 0 |
| 1 Month Change | 4.72% |
| 3 Month Change | -43.37% |
| 1 Year Change | -87.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.67% |
Recent News & Updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Shareholder Returns
| GRNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | -0.8% | 1.7% |
| 1Y | -87.4% | 4.4% | -9.6% |
Return vs Industry: GRNA underperformed the US Biotechs industry which returned 4.5% over the past year.
Return vs Market: GRNA underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| GRNA volatility | |
|---|---|
| GRNA Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GRNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: GRNA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Andrey Zarur | https://greenlightbiosciences.com |
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
GreenLight Biosciences Holdings Fundamentals Summary
| GRNA fundamental statistics | |
|---|---|
| Market Cap | US$168.22m |
| Earnings (TTM) | -US$162.96m |
| Revenue (TTM) | US$4.17m |
40.3x
P/S Ratio-1.0x
P/E RatioIs GRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRNA income statement (TTM) | |
|---|---|
| Revenue | US$4.17m |
| Cost of Revenue | US$128.11m |
| Gross Profit | -US$123.94m |
| Other Expenses | US$39.03m |
| Earnings | -US$162.96m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -2,970.69% |
| Net Profit Margin | -3,906.11% |
| Debt/Equity Ratio | 34.5% |
How did GRNA perform over the long term?
See historical performance and comparison